Drug intelligence / Profile preview

HR2502

Development stage: Preclinical
Lead developer: Nanjing Heron Pharmaceutical
Modality: Small Molecules
Administration: Intranasal

Overview

HR2502 is an innovative (Class 1) small molecule analgesic developed by Nanjing Heron Pharmaceutical for the treatment of acute pain. It is formulated for intranasal administration, a route typically utilized to achieve rapid systemic absorption and fast onset of therapeutic effect, which is critical in acute pain management. As a Class 1 drug in the Chinese regulatory framework, it represents a new chemical entity that has not been previously marketed. As of current pipeline disclosures, the specific molecular target and clinical phase have not been publicly detailed.

Beyond the preview

Go deeper on HR2502.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HR2502.

Explore the full profile